ProQR Therapeutics (PRQR) EBIT Margin (2021 - 2025)
Historic EBIT Margin for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to 391.53%.
- ProQR Therapeutics' EBIT Margin fell 1647300.0% to 391.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 288.67%, marking a year-over-year decrease of 1392000.0%. This contributed to the annual value of 161.18% for FY2024, which is 3279000.0% up from last year.
- As of Q3 2025, ProQR Therapeutics' EBIT Margin stood at 391.53%, which was down 1647300.0% from 320.91% recorded in Q2 2025.
- In the past 5 years, ProQR Therapeutics' EBIT Margin ranged from a high of 57.1% in Q2 2024 and a low of 8583.69% during Q1 2021
- Over the past 5 years, ProQR Therapeutics' median EBIT Margin value was 731.2% (recorded in 2023), while the average stood at 1834.7%.
- The largest annual percentage gain for ProQR Therapeutics' EBIT Margin in the last 5 years was 70753700bps (2022), contrasted with its biggest fall of -7658800bps (2022).
- Over the past 5 years, ProQR Therapeutics' EBIT Margin (Quarter) stood at 7250.21% in 2021, then skyrocketed by 76bps to 1730.56% in 2022, then soared by 89bps to 190.86% in 2023, then dropped by -23bps to 234.06% in 2024, then tumbled by -67bps to 391.53% in 2025.
- Its EBIT Margin stands at 391.53% for Q3 2025, versus 320.91% for Q2 2025 and 239.34% for Q1 2025.